Sovran Advisors’s AbbVie ABBV Stock Holding History

Sovran Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.02M	Buy	7,668 +590	+8%	+$127K	0.15%	157
2026 Q1	$1.5M	Buy	7,078 +177	+3%	+$39.3K	0.12%	182
2025 Q4	$1.5M	Buy	6,901 +345	+5%	+$78.6K	0.13%	179
2025 Q3	$1.5M	Buy	6,556 +1,473	+29%	+$300K	0.13%	171
2025 Q2	$965K	Buy	5,083 +1,564	+44%	+$291K	0.1%	213
2025 Q1	$609K	Buy	3,519 +375	+12%	+$72.9K	0.08%	252
2024 Q4	$552K	Buy	+3,144	New	+$578K	0.08%	241

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sovran Advisors's ABBV Position: Q2 2026 in Review

Sovran Advisors increased its AbbVie (ABBV) stake by 8.3% in Q2 2026, buying an estimated $127K and bringing the position to 7,668 shares worth $2.02M. The position accounts for 0.15% of the portfolio, ranked #157.

Sovran Advisors first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Sovran Advisors held 7,668 shares of AbbVie worth $2.02M as of Q2 2026.
Sovran Advisors bought 590 AbbVie shares in Q2 2026, an estimated $127K.
AbbVie made up 0.15% of Sovran Advisors's portfolio in Q2 2026, its #157 holding.
Sovran Advisors first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sovran Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.